Breaking News

WuXi STA Completes Acquisition of BMS Manufacturing Facility

State-of-the-art facility in Couvet, Switzerland enhances WuXi STA's drug product capacity in Europe.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

WuXi STA, a subsidiary of WuXi AppTec, has completed the acquisition of a drug product manufacturing facility in Couvet, Switzerland from Bristol Myers Squibb. WuXi STA first announced its plans to purchase the facility earlier this year. The acquisition will enhance WuXi STA’s capabilities by adding capacity to support its global partners in bringing innovative medicines to patients around the world.   The Couvet site is the first facility in Europe for WuXi STA. Opened in 2018, this facility’s...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters